Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Srinivas Raman
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed prostate adenocarcinoma with planned RT to the prostate
Baseline (pre-PAE) prostate volume ≥ 50 cc
Baseline (pre-PAE) IPSS ≥ 15
If planned or ongoing ADT and/or 5-alpha reductase inhibitor (5ARI), patient should be on therapy for at least 12 weeks, and meet prostate volume and pre-PAE IPSS criteria at the time of enrollment.
Chronic urinary retention requiring use of indwelling urinary catheter.
Neurogenic bladder or other neurological disorder that is impacting bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injuries, etc.).
Active urinary tract infections or recurrent urinary tract infections (\>2/year), prostatitis, or interstitial cystitis.
Receipt of beta blockers, antihistamines, anticonvulsants, or antispasmodics within 1 week of study treatment AND patient has not been on the same drug dosage for 6 months with a stable voiding pattern.
Hypersensitivity reactions to contrast material not manageable with prophylaxis.
Glomerular filtration rates less than 40 mL/min (unless on dialysis).
Bilateral internal iliac arterial occlusion.
Clareo Health | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
